ONC insider transaction filings
BeOne Medicines Ltd. — 50 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-09-10. Screen ONC transaction legs live →
Insider transaction summary — last 90 days
2026-06-24 to 2026-09-22, from the filings listed below: 17 Form 4 filings. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 105 legs across 17 filings by 7 insiders — 956,053 shares, $310,978,363 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 42.
- Largest priced transaction: sale of 45,044 shares @ $358.70 ($16,157,076) by OYLER JOHN, filed 2026-08-12.
By insider — same window
Open-market purchase/sale legs on non-derivative securities, grouped by the filing's reporting owner(s); joint filings appear once. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Insider | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|
| OYLER JOHN — Chief Executive Officer, Director | 7 | — | 88 legs · 907,794 sh · $294,403,656 | 22 |
| Wang Xiaodong — Director | 1 | — | 8 legs · 38,287 sh · $13,366,092 | 2 |
| Lee Chan Henry — SVP, General Counsel | 4 | — | 4 legs · 6,043 sh · $2,040,951 | 18 |
| Wu Xiaobin — President and COO | 2 | — | 2 legs · 1,572 sh · $463,327 | — |
| Rosenberg Aaron — Chief Financial Officer | 1 | — | 1 leg · 1,157 sh · $361,811 | — |
| Wang Lai — President, Global Head of R&D | 1 | — | 1 leg · 1,068 sh · $295,553 | — |
| Ball Titus B. — Principal Accounting Officer | 1 | — | 1 leg · 132 sh · $46,974 | — |
Recent Form 4 filings — BeOne Medicines Ltd.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-10 | 4 | Wang Xiaodong — Director | Sale (S): 1,181 @ $345.38 · Sale (S): 2,841 @ $346.16 · Sale (S): 1,517 @ $347.39 · Sale (S): 1,721 @ $348.01 · Option exercise (M): 31,027 @ $36.90 · Sale (S): 7,492 @ $348.31 · +4 more | EDGAR |
| 2026-09-03 | 4 | Ball Titus B. — Principal Accounting Officer | Sale (S): 132 @ $355.86 | EDGAR |
| 2026-08-27 | 4 | Wu Xiaobin — President and COO | Sale (S): 280 @ $380 | EDGAR |
| 2026-08-13 | 4 | Lee Chan Henry — SVP, General Counsel | Option exercise (M): 812 @ $194.47 · Option exercise (M): 1,058 @ $213.32 · Option exercise (M): 796 @ $159.03 · Sale (S): 2,666 @ $360 · Option exercise (M): 10,556 (derivative) @ $0 · Option exercise (M): 13,754 (derivative) @ $0 · +1 more | EDGAR |
| 2026-08-12 | 4 | OYLER JOHN — Chief Executive Officer, Director | Sale (S): 67 @ $350 · Sale (S): 2,813 @ $351.80 · Sale (S): 3,673 @ $353.32 · Sale (S): 6,717 @ $354.78 · Sale (S): 3,476 @ $355.66 · Sale (S): 12,418 @ $356.62 · +18 more | EDGAR |
| 2026-08-05 | 4 | Rosenberg Aaron — Chief Financial Officer | Sale (S): 1,157 @ $312.71 | EDGAR |
| 2026-08-03 | 4 | Lee Chan Henry — SVP, General Counsel | Sale (S): 1,044 @ $323.69 | EDGAR |
| 2026-07-24 | 4 | Lee Chan Henry — SVP, General Counsel | Option exercise (M): 514 @ $194.47 · Option exercise (M): 665 @ $213.32 · Option exercise (M): 490 @ $159.03 · Sale (S): 1,669 @ $325 · Option exercise (M): 6,682 (derivative) @ $0 · Option exercise (M): 8,645 (derivative) @ $0 · +1 more | EDGAR |
| 2026-07-22 | 4 | OYLER JOHN — Chief Executive Officer, Director | Sale (S): 5,146 @ $310.08 · Sale (S): 6,273 @ $310.75 · Sale (S): 2,907 @ $311.80 · Option exercise (M): 33,990 @ $119.96 · Sale (S): 15,499 @ $312.29 · Sale (S): 14,326 @ $312.96 · +10 more | EDGAR |
| 2026-07-17 | 4 | OYLER JOHN — Chief Executive Officer, Director | Option exercise (M): 64,628 @ $119.96 · Sale (S): 1,440 @ $305.20 · Sale (S): 597 @ $306.96 · Sale (S): 680 @ $309.05 · Sale (S): 4,833 @ $310.37 · Sale (S): 5,543 @ $311.42 · +5 more | EDGAR |
| 2026-07-17 | 4 | OYLER JOHN — Chief Executive Officer, Director | Option exercise (M): 35,605 @ $100.04 · Option exercise (M): 76,677 @ $169.58 · Option exercise (M): 4,275 @ $160.40 · Sale (S): 6,067 @ $310.02 · Sale (S): 41,336 @ $310.92 · Sale (S): 12,857 @ $311.71 · +21 more | EDGAR |
| 2026-07-14 | 4 | OYLER JOHN — Chief Executive Officer, Director | Sale (S): 4,139 @ $303.07 · Sale (S): 8,122 @ $303.93 · Option exercise (M): 97,282 @ $36.90 · Option exercise (M): 36,318 @ $100.04 · Sale (S): 39,090 @ $305.02 · Sale (S): 45,895 @ $306.21 · +4 more | EDGAR |
| 2026-07-14 | 4 | OYLER JOHN — Chief Executive Officer, Director | Option exercise (M): 11,698 @ $36.90 · Sale (S): 1,493 @ $296.07 · Sale (S): 1,314 @ $297.23 · Sale (S): 3,074 @ $298.35 · Sale (S): 5,143 @ $298.94 · Sale (S): 370 @ $300.12 · +13 more | EDGAR |
| 2026-07-10 | 4 | Lee Chan Henry — SVP, General Counsel | Option exercise (M): 202 @ $194.47 · Option exercise (M): 266 @ $213.32 · Option exercise (M): 196 @ $159.03 · Sale (S): 664 @ $302.46 · Option exercise (M): 2,626 (derivative) @ $0 · Option exercise (M): 3,458 (derivative) @ $0 · +1 more | EDGAR |
| 2026-06-25 | 4 | Wang Lai — President, Global Head of R&D | Sale (S): 1,068 @ $276.74 | EDGAR |
| 2026-06-25 | 4 | Wu Xiaobin — President and COO | Sale (S): 1,292 @ $276.26 | EDGAR |
| 2026-06-25 | 4 | OYLER JOHN — Chief Executive Officer, Director | Sale (S): 1,800 @ $273.30 · Sale (S): 1,290 @ $274.12 · Sale (S): 320 @ $275.10 | EDGAR |
| 2026-06-18 | 4 | Lee Chan Henry — SVP, General Counsel | Sale (S): 590 @ $265.98 | EDGAR |
| 2026-06-18 | 4 | Wang Lai — President, Global Head of R&D | Sale (S): 1,169 @ $265.39 | EDGAR |
| 2026-06-18 | 4 | Wu Xiaobin — President and COO | Sale (S): 1,357 @ $266.76 | EDGAR |
| 2026-06-18 | 4 | OYLER JOHN — Chief Executive Officer, Director | Sale (S): 1,650 @ $264.87 · Sale (S): 1,710 @ $265.99 · Sale (S): 333 @ $266.69 | EDGAR |
| 2026-06-15 | 4 | Mooney Elizabeth Fisher — Director | Grant/award (A): 18,980 @ $0 | EDGAR |
| 2026-06-15 | 4 | Sawyers Charles Lazelle — Director | Grant/award (A): 18,980 @ $0 | EDGAR |
| 2026-06-15 | 4 | Rosenberg Aaron — Chief Financial Officer | Grant/award (A): 71,175 @ $0 · Sale (S): 631 @ $257.74 · Grant/award (A): 137,865 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Lee Chan Henry — SVP, General Counsel | Grant/award (A): 45,071 @ $0 · Sale (S): 428 @ $257.63 · Grant/award (A): 87,308 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Dugan Margaret — Director | Grant/award (A): 18,980 @ $0 | EDGAR |
| 2026-06-15 | 4 | Riva Alessandro — Director | Grant/award (A): 18,980 @ $0 | EDGAR |
| 2026-06-15 | 4 | Wang Lai — President, Global Head of R&D | Grant/award (A): 118,625 @ $0 · Sale (S): 756 @ $261.00 · Grant/award (A): 229,775 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Wu Xiaobin — President and COO | Grant/award (A): 118,625 @ $0 · Sale (S): 626 @ $261.20 · Grant/award (A): 229,775 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | Ball Titus B. — Principal Accounting Officer | Grant/award (A): 31,213 @ $0 · Sale (S): 49 @ $256.39 · Sale (S): 120 @ $257.53 | EDGAR |
| 2026-06-15 | 4 | Wang Xiaodong — Director | Grant/award (A): 99,892 @ $0 · Grant/award (A): 193,492 (derivative) @ $0 | EDGAR |
| 2026-06-15 | 4 | BRANDICOURT OLIVIER — Director | Grant/award (A): 18,980 @ $0 | EDGAR |
| 2026-06-15 | 4 | Sharp Shalini — Director | Grant/award (A): 18,980 @ $0 | EDGAR |
| 2026-06-15 | 4 | HOOPER ANTHONY C — Director | Grant/award (A): 18,980 @ $0 | EDGAR |
| 2026-06-15 | 4 | BAKER BROS. ADVISORS LP — Director 667, L.P. — Director Baker Bros. Advisors (GP) LLC — Director Baker Brothers Life Sciences LP — Director BAKER FELIX — Director BAKER JULIAN — Director | Grant/award (A): 18,980 @ $0 · Grant/award (A): 18,980 @ $0 | EDGAR |
| 2026-06-15 | 4 | OYLER JOHN — Chief Executive Officer, Director | Grant/award (A): 177,931 @ $0 · Sale (S): 741 @ $256.23 · Sale (S): 859 @ $257.59 · Sale (S): 200 @ $258.28 · Sale (S): 149 @ $258.81 · Grant/award (A): 344,669 (derivative) @ $0 | EDGAR |
| 2026-06-10 | 4 | Lee Chan Henry — SVP, General Counsel | Sale (S): 711 @ $270.24 · Sale (S): 160 @ $271.26 | EDGAR |
| 2026-06-10 | 4 | Wang Lai — President, Global Head of R&D | Sale (S): 1,327 @ $269.34 · Sale (S): 40 @ $270.73 | EDGAR |
| 2026-06-10 | 4 | Wu Xiaobin — President and COO | Sale (S): 1,444 @ $269.33 · Sale (S): 40 @ $270.55 | EDGAR |
| 2026-06-10 | 4 | Ball Titus B. — Principal Accounting Officer | Sale (S): 100 @ $271.06 · Sale (S): 36 @ $272.08 | EDGAR |
| 2026-06-10 | 4 | OYLER JOHN — Chief Executive Officer, Director | Sale (S): 3,820 @ $270.38 · Sale (S): 1,120 @ $271.14 | EDGAR |
| 2026-06-03 | 4 | Yi Qingqing — Director | Sale (S): 235 @ $279.13 | EDGAR |
| 2026-05-27 | 4 | Dugan Margaret — Director | Sale (S): 212 @ $309.60 | EDGAR |
| 2026-05-27 | 4 | Riva Alessandro — Director | Sale (S): 212 @ $309.51 | EDGAR |
| 2026-05-27 | 4 | Sanders Corazon (Corsee) D. — Director | Sale (S): 212 @ $309.59 | EDGAR |
| 2026-05-27 | 4 | BAKER BROS. ADVISORS LP — Director 667, L.P. — Director Baker Bros. Advisors (GP) LLC — Director Baker Brothers Life Sciences LP — Director BAKER FELIX — Director BAKER JULIAN — Director | Sale (S): 2,743 @ $23.85 · Sale (S): 2,743 @ $23.85 · Sale (S): 2,756 @ $23.79 · Sale (S): 2,756 @ $23.79 | EDGAR |
| 2026-05-15 | 4 | Lee Chan Henry — SVP, General Counsel | Option exercise (M): 101 @ $194.47 · Option exercise (M): 133 @ $213.32 · Option exercise (M): 98 @ $159.03 · Sale (S): 332 @ $310.72 · Option exercise (M): 1,313 (derivative) @ $0 · Option exercise (M): 1,729 (derivative) @ $0 · +1 more | EDGAR |
| 2026-04-10 | 4 | Lee Chan Henry — SVP, General Counsel | Option exercise (M): 101 @ $194.47 · Option exercise (M): 133 @ $213.32 · Option exercise (M): 98 @ $159.03 · Sale (S): 332 @ $311.59 · Option exercise (M): 1,313 (derivative) @ $0 · Option exercise (M): 1,729 (derivative) @ $0 · +1 more | EDGAR |
| 2026-03-13 | 4 | Lee Chan Henry — SVP, General Counsel | Option exercise (M): 110 @ $194.47 · Option exercise (M): 133 @ $213.32 · Option exercise (M): 98 @ $159.03 · Sale (S): 341 @ $300 · Option exercise (M): 1,430 (derivative) @ $0 · Option exercise (M): 1,729 (derivative) @ $0 · +1 more | EDGAR |
| 2026-03-10 | 4 | OYLER JOHN — Chief Executive Officer, Director | Grant/award (A): 326,976 @ $0 · Grant/award (A): 117,936 @ $0 | EDGAR |
Recent 8-K events — BeOne Medicines Ltd.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-26 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-26 | 8-K | 8.01 — Other Events | EDGAR |
| 2026-06-11 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-15 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-02-26 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-12-19 | 8-K | 1.02 — Termination of a Material Definitive Agreement | EDGAR |
| 2025-12-18 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=ONC returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →